research Efficacy and Safety Evaluations of Topical Proretinal Nanoparticles
Proretinal nanoparticles are a safe and effective way to deliver retinal to the skin.
Search
forLearn
0 / 0 results — no results
Research
5 / 78 results 
research Structure Optimization of Tetrahydropyridoindole-Based Aldose Reductase Inhibitors Improved Their Efficacy and Selectivity
Optimizing the structure of a specific compound greatly improved its effectiveness and precision for treating diabetic complications.
research Development of Novel Indole-Based Bifunctional Aldose Reductase Inhibitors and Antioxidants as Promising Drugs for the Treatment of Diabetic Complications
New indole-based compounds, particularly cemtirestat, show promise as dual-function drugs for diabetic complications.
research Does Inhibition of Aldose Reductase Contribute to the Anti-Inflammatory Action of Setipiprant?
Setipiprant may reduce inflammation by blocking an enzyme called aldose reductase.
research Risks And Side Effects In The Medical Management Of Benign Prostatic Hyperplasia
Community Join
5 / 20 resultscommunity Earliest we can get legitimate pyrilutamide
Pyrilutamide, a drug in phase 3 trials in China, potentially becoming available in late 2023 or early 2024; Finasteride being used as a current treatment for hair loss; and the possibility of joining a group buy for black market versions of Pyrilutamide.
community The Cure isn't 5 years away; it's already here.
PP405 is a new topical treatment for hair loss, showing promise in trials but still requires finasteride for maintenance. There is skepticism about its effectiveness and safety, with concerns about needing finasteride to maintain results.
community New molecule PP405 vs exercise
PP405 targets hair follicle stem cells differently than exercise-induced lactate, suggesting exercise alone may not replicate its benefits. Minoxidil and finasteride are recommended alongside exercise for hair regrowth, with additional suggestions like spicy food and infrared exposure.
community Phase II for Technoderma Therepeutic's TDM-105795 set to begin in April tentatively
Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.
community Some good news for the future.
PP-405, a potential hair loss treatment, shows promise in stimulating dormant hair follicles and may help with various hair loss types. Current treatments like Minoxidil are still recommended as PP-405 is in early trials and may take years to become available.